Effect of melatonin on methamphetamine- and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine- induced behavioral sensitization

Neuropharmacology

Volumn 37, Issue 6, 1998, Pages 781-791

  Itzhak, Yossef ^a   Martin, Julio L ^a   Dean Black, M ^a   Ali, Syed F ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Dopaminergic neurotoxicity; Free radicals; Locomotor activity; Melatonin; Methamphetamine; MPTP; Sensitization

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; FREE RADICAL; HOMOVANILLIC ACID; MAZINDOL; MELATONIN; METHAMPHETAMINE; PSYCHOSTIMULANT AGENT; TRITIUM;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; HORMONAL REGULATION; HYPERTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANIMALS; BODY TEMPERATURE; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MELATONIN; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; MICE; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; NERVE TISSUE PROTEINS;

EID: 0031839674     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00067-7     Document Type: Article

References (48)

1. Acuna-Castroviejo D., Coto-Montes A., Monti M.G., Ortiz G.G., Reiter R.J. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60:1997;PL23-29.
2. Ali S.F., Newport G.D., Holson R.R., Slikker W. Jr., Bowyer J.F. Low environmental temperature or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res. 658:1994;33-38.
3. Bettahi I., Pozo D., Osuna C., Reiter R.J., Acuna-Castroviejo D., Guerrero J.M. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J. Pineal Res. 20:1996;205-210.
4. Bowyer J.F., Tank A.W., Newport G.D., Slikker W. Jr., Ali S.F., Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J. Pharmacol. Exp. Ther. 260:1992;817-824.
5. Cadet J.L., Sheng P., Ali S.F., Rothman R., Carlson E., Epstein C.J. Attenuation of methamphetamine -induced neurotoxicity in copper-zinc superoxide dismutase transgenic mice. J. Neurochem. 62:1994;380-383.
6. Cadet J.L., Ordonez S.V., Ordonez J.V. Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Synapse. 25:1997;176-184.
7. Cappon G.D., Broening H.W., Pu C., Morford L., Vorhees C.V. α-Phenyl-N-tert-butyl nitrone attenuates methamphetamine-induced depletion of striatal dopamine without altering hyperthermia. Synapse. 24:1996;173-181.
8. Chan P., Delanney L.E., Irwin I., Langston J.W., Di Monte D.A. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57:1991;348-351.
9. +. Free Radic. Biol. Med. 13:1992;581-583.
10. De Vito M.J., Wagner G.C. Methamphetamine-induced neuronal damage: A possible role for free radicals. Neuropharmacology. 28:1989;1145-1150.
11. +-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Res. 715:1996;1-8.
12. Di Monte D.A., Royland J.E., Jakowec M.W., Langston J.W. Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase. J. Neurochem. 67:1996;2443-2450.
13. Escames G., Guerrero J.M., Reiter R.J., Garcia J.J., Munoz-Hoyos A., Ortiz G.G., Oh C.S. Melatonin and vitamin E limit nitric oxide-induced lipid peroxidation in rat brain homogenates. Neurosci. Lett. 230:1997;147-150.
14. Fornai F., Vaglini F., Maggio R., Bonuccelli U., Corsini G.U. Species differences in the role of excitatory amino acids in experimental Parkinsonism. Neurosci. Biobehav. Rev. 21:1997;401-415.
15. Fuller R.W., Hemrick-Luecke S. Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats. Science. 209:1980;305-307.
16. Gibb J.M., Bush L., Hanson G.R. Exacerbation of methamphetamine-induced neurochemical deficits by melatonin. J. Pharmacol. Exp. Ther. 283:1997;630-635.
17. Gilad E., Cuzzocrea S., Zingarelli B., Salzmaan A.L., Szabo C. Melatonin is a scavenger of peroxynitrite. Life Sci. 60:1997;169-174.
18. Giovanni A., Liang L.P., Hastings T.G., Zigmond M.J. Estimating hydroxy radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64:1995;1819-1825.
19. +) induces NADH-dependent superoxide formation, and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1990;1049-1055.
20. Heikkila R.E., Hess A., Duvosin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-12,3,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
21. Itzhak Y. Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase. J. Pharmacol. Exp. Ther. 282:1997;521-527.
22. Itzhak Y., Ali S.F. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J. Neurochem. 67:1996;1770-1773.
23. Itzhak Y., Martin J.L., Ali S.F., Norenberg M.D. Depletion of striatal dopamine transporter does not affect psychostimulant-induced locomotor activity. Neuroreport. 8:1997;3245-3249.
24. Itzhak Y., Gandia C., Huang P.L., Ali S.F. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J. Pharmacol. Exp. Ther. 284:1998;1040-1047.
25. Kogan F.J., Nichols W.K., Gibb J.W. Influence of methamphetamine on nigra and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36:1976;363-371.
26. Kuperman D.I., Freyladenhoven T.F., Schmued L., Ali S.F. Methamphetamine-induced hyperthermia in mice: examination of dopamine depletion and heat shock protein induction. Brain Res. 771:1997;221-227.
27. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
28. Lowry O.H., Rosebrrough N.J., Farr A.L., Randall R.J. Protein measurements with Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
29. Melchiorri D., Reiter R.J., Attia A., Hara M., Burgos A., Nistico G. Potent protective effect of melatonin on in vivo paraquate induced toxicity. Life Sci. 56:1995;83-88.
30. Miller D.B., O'Callagahan J.P. Environmental-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270:1994;752-760.
31. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
32. Pierrefiche G., Topall G., Courboin G., Henriet I., Laborit H. Antioxidant activity of melatonin in mice. Res. Commun. Chem. Pathol. Pharmacol. 80:1993;211-223.
33. Pozo D. Inhibition of nitric oxide synthase and cyclic GMP production by physiological concentrations of melatonin in rat cerebellum: a calmodulin-mediated mechanism. J. Cell. Biochem. 65:1997;430-442.
34. Pozo D., Reiter R.J., Calvo J.R., Guerrero J.M. Physiological concentration of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci. 55:1994;455-460.
35. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
36. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA. 93:1996;4565-4571.
37. Reiter R.J., Melchiorri D., Sewerynek E., Poeggeler B., Barlow-Walden L., Chuang J., Ortiz G.G., Acuna-Castroviejo D.A. A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res. 18:1995;869-875.
38. Reiter R.J. Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. Eur. J. Endocrinol. 134:1996;412-420.
39. Reiter R.J., Rang L., Garcia J.J., Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 60:1997;2255-2272.
40. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396:1986;157-198.
41. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18:1993;247-291.
42. Schulz J.B., Matthews R.T., Muqit M.M.K., Browne S.E., Beal M.F. Inhibition of neuronal nitric oxide synthase protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64:1995;936-939.
43. Segal D.S., Kuczenski R. An escalating dose 'binge' model of amphetamine psychosis: behavioral and neurochemical characteristics. J. Neurosci. 17:1997;2551-2566.
44. Seiden L.S., Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of rat brain after a single large dose of methamphetamine. Pharmacol. Biochem. Behav. 21:1984;29-31.
45. Sheng P., Cerruit C., Ali S.F., Cadet J.L. Nitric oxide is a mediator of methamphetamine-induced neurotoxicity: in vitro evidence from primary cultures of mesencephalic cells. Ann. NY Acad. Sci. 801:1996;174-186.
46. Sonsalla, P.K., Nicklas, W.J., 1992. MPTP and animal models of Parkinson's disease. In: Koller W.C. (Ed.), Handbook of Parkinson's Disease, 2nd ed. Marcel Dekker, New York, pp. 319-340.
47. Wagner G.C., Ricaurte G.A., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletion of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181:1980;151-160.
48. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med. 2:1996;699-703.